JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
 QUICK SEARCH:   [advanced]


     


First published online June 15, 2007
J Nucl Med 2007, doi:10.2967/jnumed.107.039578
© 2007 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.107.039578v1
48/7/1207    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Treyer, V.
Right arrow Articles by Buck, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Treyer, V.
Right arrow Articles by Buck, A.


Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods

Valerie Treyer 1, Johannes Streffer 2, Matthias T. Wyss 1, Andrea Bettio 3, Simon M. Ametamey 3, Uta Fischer 2, Mark Schmidt 4, Fabrizio Gasparini 5, Christoph Hock 2, and Alfred Buck 1*

1 PET Center, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
2 Division of Psychiatry Research, University of Zurich, Zurich, Switzerland
3 Center for Radiopharmaceutical Science of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, Zurich, Zurich, Switzerland
4 Novartis Pharma AG, Basel, Switzerland
5 Novartis Institutes for Biomedical Research, Basel, Switzerland

* To whom correspondence should be addressed. E-mail: fred.buck{at}usz.ch.


   Abstract

11C-ABP688 is a new PET ligand to assess the subtype 5 metabotropic glutamate receptor (mGlu5). The purpose of this study was to evaluate different methods for the analysis of human 11C-ABP688 data acquired from 6 healthy, young volunteers. Methods: The methods were a 1-tissue-compartment model (K1, k2''), a 2-tissue-compartment model (K1-k4), and the noncompartmental method developed by Logan. Parameters related to receptor density were the total distribution volume (DV), DV'' (= K1/k2'', 1 tissue compartment); specific DV, DVC2 (= K1/k2' x k3'/k4, 2 tissue compartments); and DVtot for the noncompartmental method. Results: The 1-tissue-compartment model was too simple to adequately fit the data. DVC2 calculated with the 2-tissue-compartment model ranged from 5.45 ± 1.47 (anterior cingulate) to 1.91 ± 0.32 (cerebellum). The corresponding values for DVtot, calculated with the 2-tissue-compartment model and the Logan method (in parentheses), were 6.57 ± 1.45 (6.35 ± 1.32) and 2.93 ± 0.53 (2.48 ± 0.40). There was no clear evidence of a region devoid of mGlu5 receptors. The first-pass extraction fraction exceeded 95%. The minimal scan duration to obtain stable results was estimated to be 45 min. Conclusion: 11C-ABP688 displays favorable kinetics for assessing mGlu5 receptors. For tracer kinetic modeling, 2-tissue-compartment models are clearly superior to models with only 1 tissue compartment. In comparison to the compartmental models, the Logan method is equally useful if only DVtot values are required and fast pixelwise parametric maps are desired. The lack of regions devoid of receptors limits the use of reference region methods that do not require arterial blood sampling. Another advantage of the tracer is the fast kinetics that allow for relatively short acquisitions.

Key Words: positron emission tomography, kinetic modeling, molecular imaging, mGlu5, 11C-ABP688




This article has been cited by other articles:


Home page
JNMHome page
C. J. Endres, M. G. Pomper, M. James, O. Uzuner, D. A. Hammoud, C. C. Watkins, A. Reynolds, J. Hilton, R. F. Dannals, and M. Kassiou
Initial Evaluation of 11C-DPA-713, a Novel TSPO PET Ligand, in Humans
J. Nucl. Med., August 1, 2009; 50(8): 1276 - 1282.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.